Siemens Healthineers Unveils 60-Second Radiation Therapy Platform at Boston Oncology Summit
Published on 09/28/2026 at 15:51 | Editorial boerse-global.de
Siemens Healthineers used the opening day of the American Society for Radiation Oncology (ASTRO) annual meeting in Boston to pull back the curtain on Accela, a radiation therapy system it says can deliver stereotactic treatment to multiple targets in roughly one minute. Investors liked what they saw: the stock climbed 3.1% in Friday trading to EUR 38.98.
At the heart of the platform is NeoArc, a software-driven technology built around dynamically modulated arc therapy (NeoArc DMAT). According to the German medical technology group, the system enables stereotactic irradiation during a single breath-hold, compressing multi-site SBRT procedures — where several lesions are treated at once — into about 60 seconds. Planning software underpinned by artificial intelligence and mathematical optimization algorithms lets clinical teams trade off plan quality against treatment speed, with the broader aim of cutting both time on the treatment couch and the overall course of care.
Clinical Heavyweights Behind the Design
A roster of international cancer centers contributed to the development and scientific evaluation of Accela and NeoArc. Among the advising institutions were the Mayo Clinic, Mass General Brigham Cancer Institute, University Hospital Zurich and Memorial Sloan Kettering Cancer Center, with additional clinical input from Washington University School of Medicine in St. Louis.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Separately, radiation therapy specialist Sun Nuclear said its AdaptCHECK software has been validated for use alongside Accela. The program handles quality assurance for adaptive radiation through independent dose checks and log files without disrupting clinical workflows.
FDA Clearance Still Pending
Commercial rollout faces one remaining hurdle: the system is awaiting 510(k) clearance from the U.S. Food and Drug Administration and is not yet approved for sale in any market. Siemens Healthineers intends to press its advantage in radio-oncology equipment once that green light arrives.
The Boston presentation caps a busy stretch of operational moves this month. On September 16, the company brought its CN-3000 and CN-6000 coagulation testing systems to the U.S. laboratory market. Five days later, on September 21, it struck a collaboration with Novo aimed at widening access to non-invasive blood tests for the liver diseases MASLD and MASH. Roughly two weeks ago, Siemens Healthineers expanded its manufacturing footprint in medical technology by opening a sensor plant in Forchheim, a project that absorbed around EUR 100 million.
A Rough Year for the Share Price
Friday's advance followed a 2.0% gain on the prior session, when the stock closed at EUR 37.89 ahead of the product unveiling. Even so, the shares remain down 16% since the start of the year, leaving plenty of ground to recover as the company waits on U.S. regulators and prepares to take Accela to market.
Ad
Siemens Healthineers Stock: New Analysis - 28 September
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
